Business
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
SOUTH SAN FRANCISCO, Calif., December 10, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/76f232c4e38c5393c46196cfa4ffcc57"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EpiRsFbzaF0bg5V3niwEyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/76f232c4e38c5393c46196cfa4ffcc57","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HlUMNCC2XJPfdjZuLRcQrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/76f232c4e38c5393c46196cfa4ffcc57","width":1121,"height":442}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., December 10, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers in Drug Delivery.","length":534,"tagName":"p"},{"type":"text","content":"Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "This new Frontiers in Drug Delivery publication highlights the potential for clinical utility of our lead asset, eDSP, across pulmonary and IBD indications. The purpose of these prior studies was to demonstrate that eDSP can be delivered at efficacious doses while avoiding the frequent and debilitating common toxicities associated with chronic corticosteroid therapy. Importantly, it also speaks to the potential of eDSP to transform treatment paradigms across multiple diseases where chronic corticosteroid treatment is – or has the potential to become – the standard of care. As we rapidly approach topline results in the middle of the first quarter of 2026 for our Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia (A-T), we believe these data further underscore not only the ability of eDSP to deliver corticosteroid efficacy without toxicities, but also highlight the significant pipeline expansion opportunities that lie ahead of Quince,...